RT Journal Article
SR Electronic
T1 Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2913
VO 40
IS Suppl 56
A1 Nobuyuki Koyama
A1 Shohei Minesaki
A1 Susumu Yamazaki
A1 Harue Utsugi
A1 Yuri Maeno
A1 Tetsuya Okano
A1 Yoshitake Murayama
A1 Kunihiko Kobayashi
YR 2012
UL http://erj.ersjournals.com/content/40/Suppl_56/P2913.abstract
AB [Backgound] Bevacizumab (BEV), a humanized monoclonal antibody against vascular endothelial growth factor, is one of molecular targeting agents for non-small lung cancer (NSCLC). The aim of this study is to evaluate the efficacy of BEV in clinical practice. [Methods] We retrospectively investigated the clinicopathological characteristics of 26 NSCLC patietnts who had undergone BEV therapy in Saitama Medical University International Medical Center and Saitama Medical University Hospital. [Results] The patients had a median age of 64 years (range, 33 to 75 years), and 19 males and current smokers. Epidermal growth factor receptor gene mutations were found in 6 patients (23%). Combined with BEV, each half of 26 patients received the chemotherapeutic regimen of either carboplatin/paclitaxel or carboplatin/pemetrexed. Objective response rate was 54% and disease control rate was 96%, and median progression free survival and overall survival were 100 days and 202 days, respectively. Adverse events included 4% of arrhythmia, 27% of hypertension, 8% of lower gastrointestinal bleeding, 19% of nasal bleeding, and 23% of proteinuria. Using Kaplan-Meier survival curves and logrank tests, therapeutic response influenced neither progression free survival nor overall survival, whereas longer overall survival was observed in NSCLC patients treated with pemetrexed-containing chemotherapy after failure of BEV. [Conclusion] Therapeutic response to BEV does not predict survival benefit of BEV-treated NSCLC patients. Meanwhile, pemetrexed may be a novel therapeutic option for NSCLC patients who have failed BEV treatment.